These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 16077423

  • 1. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy.
    McCurry KR, Iacono A, Zeevi A, Yousem S, Girnita A, Husain S, Zaldonis D, Johnson B, Hattler BG, Starzl TE.
    J Thorac Cardiovasc Surg; 2005 Aug; 130(2):528-37. PubMed ID: 16077423
    [Abstract] [Full Text] [Related]

  • 2. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath.
    Shapiro R, Basu A, Tan H, Gray E, Kahn A, Randhawa P, Murase N, Zeevi A, Girnita A, Metes D, Ness R, Bass DC, Demetris AJ, Fung JJ, Marcos A, Starzl TE.
    J Am Coll Surg; 2005 Apr; 200(4):505-15; quiz A59-61. PubMed ID: 15804464
    [Abstract] [Full Text] [Related]

  • 3. Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation.
    Tan HP, Kaczorowski D, Basu A, McCauley J, Marcos A, Donaldson J, Unruh M, Randhawa P, Zeevi A, Shapiro R.
    Transplant Proc; 2005 Dec; 37(10):4235-40. PubMed ID: 16387087
    [Abstract] [Full Text] [Related]

  • 4. Five-year outcomes with alemtuzumab induction after lung transplantation.
    Shyu S, Dew MA, Pilewski JM, DeVito Dabbs AJ, Zaldonis DB, Studer SM, Crespo MM, Toyoda Y, Bermudez CA, McCurry KR.
    J Heart Lung Transplant; 2011 Jul; 30(7):743-54. PubMed ID: 21420318
    [Abstract] [Full Text] [Related]

  • 5. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.
    Thomas PG, Woodside KJ, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK.
    Transplantation; 2007 Jun 15; 83(11):1509-12. PubMed ID: 17565326
    [Abstract] [Full Text] [Related]

  • 6. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus.
    Marcos A, Eghtesad B, Fung JJ, Fontes P, Patel K, Devera M, Marsh W, Gayowski T, Demetris AJ, Gray EA, Flynn B, Zeevi A, Murase N, Starzl TE.
    Transplantation; 2004 Oct 15; 78(7):966-71. PubMed ID: 15480160
    [Abstract] [Full Text] [Related]

  • 7. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning.
    Shapiro R, Jordan ML, Basu A, Scantlebury V, Potdar S, Tan HP, Gray EA, Randhawa PS, Murase N, Zeevi A, Demetris AJ, Woodward J, Marcos A, Fung JJ, Starzl TE.
    Ann Surg; 2003 Oct 15; 238(4):520-5; discussion 525-7. PubMed ID: 14530723
    [Abstract] [Full Text] [Related]

  • 8. Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation.
    Shapiro R, Ellis D, Tan HP, Moritz ML, Basu A, Vats AN, Khan AS, Gray EA, Zeevi A, McFeaters C, James G, Jo Grosso M, Marcos A, Starzl TE.
    J Pediatr; 2006 Jun 15; 148(6):813-8. PubMed ID: 16769394
    [Abstract] [Full Text] [Related]

  • 9. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes.
    Thai NL, Khan A, Tom K, Blisard D, Basu A, Tan HP, Marcos A, Fung JJ, Starzl TE, Shapiro R.
    Transplantation; 2006 Dec 27; 82(12):1621-4. PubMed ID: 17198247
    [Abstract] [Full Text] [Related]

  • 10. Campath-1H in renal transplantation: The University of Wisconsin experience.
    Knechtle SJ, Fernandez LA, Pirsch JD, Becker BN, Chin LT, Becker YT, Odorico JS, D'alessandro AM, Sollinger HW.
    Surgery; 2004 Oct 27; 136(4):754-60. PubMed ID: 15467659
    [Abstract] [Full Text] [Related]

  • 11. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results.
    Kaufman DB, Leventhal JR, Gallon LG, Parker MA.
    Am J Transplant; 2006 Feb 27; 6(2):331-9. PubMed ID: 16426317
    [Abstract] [Full Text] [Related]

  • 12. The impact of Campath 1H induction in adult liver allotransplantation.
    Tryphonopoulos P, Madariaga JR, Kato T, Nishida S, Levi DM, Moon J, Selvaggi G, De Faria W, Regev A, Bejarano P, Khaled A, Safdar K, Esquenazi V, Weppler D, Yoshida H, Ruiz P, Miller J, Tzakis AG.
    Transplant Proc; 2005 Mar 27; 37(2):1203-4. PubMed ID: 15848669
    [Abstract] [Full Text] [Related]

  • 13. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
    Muñoz AS, Cabanayan-Casasola CB, Danguilan RA, Padua FB, Ona ET.
    Transplant Proc; 2008 Sep 27; 40(7):2230-3. PubMed ID: 18790200
    [Abstract] [Full Text] [Related]

  • 14. [Preliminary experience with Campath 1H induction combined with low-dose monotherapy of tacrolimus in small bowel transplantation].
    Li YX, Li N, Ni XD, Li YS, Li M, Shen J, Li JS.
    Zhonghua Wai Ke Za Zhi; 2009 Jun 01; 47(11):810-3. PubMed ID: 19961008
    [Abstract] [Full Text] [Related]

  • 15. Early outcomes using alemtuzumab induction in lung transplantation.
    van Loenhout KC, Groves SC, Galazka M, Sherman B, Britt E, Garcia J, Griffith B, Iacono A.
    Interact Cardiovasc Thorac Surg; 2010 Feb 01; 10(2):190-4. PubMed ID: 19939852
    [Abstract] [Full Text] [Related]

  • 16. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
    Zanfi C, Lauro A, Cescon M, Dazzi A, Ercolani G, Grazi GL, Zanello M, Vivarelli M, Del Gaudio M, Ravaioli M, Cucchetti A, Vetrone G, Tuci F, Di Gioia P, Lazzarotto T, D'Errico A, Bagni A, Faenza S, Siniscalchi A, Pironi L, Pinna AD.
    Transplant Proc; 2010 Feb 01; 42(1):35-8. PubMed ID: 20172276
    [Abstract] [Full Text] [Related]

  • 17. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience.
    Tan HP, Kaczorowski DJ, Basu A, Khan A, McCauley J, Marcos A, Fung JJ, Starzl TE, Shapiro R.
    Transplantation; 2004 Dec 15; 78(11):1683-8. PubMed ID: 15591960
    [Abstract] [Full Text] [Related]

  • 18. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
    Trzonkowski P, Zilvetti M, Friend P, Wood KJ.
    Transplantation; 2006 Nov 27; 82(10):1342-51. PubMed ID: 17130784
    [Abstract] [Full Text] [Related]

  • 19. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial.
    Margreiter R, Klempnauer J, Neuhaus P, Muehlbacher F, Boesmueller C, Calne RY.
    Am J Transplant; 2008 Jul 27; 8(7):1480-5. PubMed ID: 18510632
    [Abstract] [Full Text] [Related]

  • 20. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM, Yang SL, Wu WZ, Tan JM.
    Chin Med J (Engl); 2011 Mar 27; 124(5):664-8. PubMed ID: 21518554
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.